ARGENX SE
About ARGENX SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $55.4B
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $55.4B
- Shares outstanding
- 62.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 18, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 5% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ARGENX SE.
Write a review
News about ARGENX SE
News & sentiment via Polygon.io
